Cross-clade immunogenicity and antigen-sparing with an AS03A-adjuvanted prepandemic influenza vaccine in a Thai population

Journal of the Medical Association of Thailand

Volumn 94, Issue 8, 2011, Pages 916-926

  Thongcharoen, Prasert ^a   Auewarakul, Prasert ^a   Hutagalung, Yanee ^b   Ong, Gary ^b   Gillard, Paul ^b   Drame, Mamadou ^b   Bock, Hans L ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant system; H5N1; Influenza; Prepandemic; Thailand

Indexed keywords

ALPHA TOCOPHEROL; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; POLYSORBATE 80; SQUALENE; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; ASIAN; CLADISTICS; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE URTICARIA; MALE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PANDEMIC INFLUENZA; PHASE 3 CLINICAL TRIAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SEROCONVERSION; SINGLE BLIND PROCEDURE; THAILAND; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; THAILAND; VACCINATION; YOUNG ADULT;

EID: 79961186873     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Skeik N, Jabr FI. Influenza viruses and the evolution of avian influenza virus H5N1. Int J Infect Dis 2008; 12: 233-238.
2. Sellwood C, Asgari-Jirhandeh N, Salimee S. Bird flu: if or when? Planning for the next pandemic. Postgrad Med J 2007; 83: 445-450.
3. Goodman C, Mukherjee D, Faulkner E. How effective would antiviral vaccination and antiviral drug prevention and treatment strategies be for reducing the impact of the next influenza pandemic? [database on the Internet]. Copenhagen: WHO Regional Office for Europe; 2006 [cited 2007 Nov 20]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0003/74658/E88034.pdf
4. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8: 650-658.
5. Chen H, Smith GJ, Li KS, Wang J, Fan XH, Rayner JM, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A 2006; 103: 2845-2850.
6. Salzberg SL, Kingsford C, Cattoli G, Spiro DJ, Janies DA, Aly MM, et al. Genome analysis linking recent European and African influenza (H5N1) viruses. Emerg Infect Dis 2007; 13: 713-718.
7. World Health Organization. Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005; 11: 1515-1521.
8. World Health Organization (WHO). Global Alert and Response (GAR). Continuing progress towards a unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses [database on the Internet]. Updated March 2009 [cited 2009 Mar 10]. Available from: http://www.who.int/csr/disease/avian_influenza/guidelines/nomenclature/en/
9. Li WC, Huang YC. Development of vaccines against influenza A virus (H5N1). Chang Gung Med J 2007; 30: 294-304.
10. World Health Organization. Pandemic (H1N1) 2009, update 59 [database on the Internet]. 2009 [cited 2010 Apr 16]. Available from: http://www.who.int/csr/don/2010_04_09/en/index.html
11. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/ (H5N1) [database on the Internet]. 09 April 2010 [cited 2010 Apr 16]. Available from: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_04_09/en/index.html
12. Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza-Mataftsi E. Influenza A(H5N1): an overview of the current situation. Euro Surveill 2009; 14: pii:19216.
13. Suwannakarn K, Amonsin A, Sasipreeyajan J, Kitikoon P, Tantilertcharoen R, Parchariyanon S, Chaisingh A, Nuansrichay B, Songserm T, Theamboonlers A, Poovorawan Y. Molecular evolution of H5N1 in Thailand between 2004 and 2008. Infect Genet Evol 2009; 9: 896-902.
14. The Second National Strategic Plan for Prevention and Control of Avian Influenza and Preparedness for Influenza Pandemic (B.E. 2551-2553) (A.D. 2008- 2010). Sub-committee for the Second National Strategic Plan for Prevention and Control of Avian Influenza and Preparedness for Influenza Pandemic. Bangkok: Veterans Press; 2007.
15. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370: 580-589.
16. World Health Organization. H5N1 avian influenza: timeline [database on the Internet]. Geneva: WHO; 2006 [cited 2008 Sep 1]. Available from: http://www.who.int/csr/disease/avian_influenza/timeline.pdf
17. Longini IM Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, et al. Containing pandemic influenza at the source. Science 2005; 309: 1083-1087.
18. World Health Organization. Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile [database on the Internet]. WHO scientific consultation. Geneva, Switzerland 1-3 October 2007 [cited 2008 Nov 12]. Available from: http://www.who.int/csr/resources/publications/WHO_HSE_EPR_GIP_2008_1/en/index.html
19. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368: 991-997.
20. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343-1351.
21. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19: 1732-1737.
22. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367: 1657-1664.
23. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357: 1937-1943.
24. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad Clade 2 crossreactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3: e1665.
25. Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27: 7428-7435.
26. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/ Singapore/97 vaccine. Virus Res 2004; 103: 91-95.
27. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27: 493-497.
28. Committee for Human Medicinal Products (CHMP). Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. EMEA/CHMP/VWP/263499/ 2006 [database on the Internet]. January 2007 [cited 2009 Mar 9]. Available from: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003804
29. Committee for Human Medicinal Products (CHMP). Guideline on dossier structure and content for pandemic influenza vaccine marketing authorization application (revision). EMEA/CPMP/ VEG/4717/2003-Rev.1 [database on the Internet]. December 2008 [cited 2009 Mar 17]. Available from: http://www.ema.europa.eu/ema/pages/ContentId=WC500003869
30. Auewarakul P. The past and present threat of avian influenza in Thailand. In: Lu Y, Essex M, Roberts B, editors. Emerging infections in Asia [database on the Internet]. 2008 [cited 2009 Jan 20]. Available from: http://www.springer.com/978-0-387-75721-6
31. Chunsuttiwat S. Response to avian influenza and preparedness for pandemic influenza: Thailand's experience. Respirology 2008; 13 (Suppl 1): S36-S40.
32. Oshitani H, Kamigaki T, Suzuki A. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2008; 14: 875-880.
33. World Health Organization. Media centre. Projected supply of pandemic influenza vaccine sharply increases [database on the Internet]. 2007 [cited 2009 Mar 18]. Available from: http://www.who.int/mediacentre/news/releases/2007/pr60/en/index.html
34. Amonsin A, Chutinimitkul S, Pariyothorn N, Songserm T, Damrongwantanapokin S, Puranaveja S, et al. Genetic characterization of influenza A viruses (H5N1) isolated from 3rd wave of Thailand AI outbreaks. Virus Res 2006; 122: 194-199.
35. Chutinimitkul S, Songserm T, Amonsin A, Payungporn S, Suwannakarn K, Damrongwatanapokin S, et al. New strain of influenza A virus (H5N1), Thailand. Emerg Infect Dis 2007; 13: 506-507.
36. World Health Organization Global Influenza Program Surveillance Network. Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005; 11: 1515-1521.
37. European Medicines Agency. Summary of Product Characteristics. Prepandrix, H5N1 prepandemic influenza vaccine [database on the Internet]. 2009 [cited 2010 May 7]. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/prepandrix/emea-combined-h822en.pdf